DYN, Trendline bounce on the 1hr chart coming up. Long on a bounce at $26, short on trendline break. Possibly 20% either side. Multiple PT upgrades last week and only 15% float is retail hence the big % daily moves.
−3.94USD
−235.94 MUSD
51.59 M
About Dyne Therapeutics, Inc.
Sector
Industry
CEO
John G. Cox
Website
Headquarters
Waltham
Employees (FY)
141
Founded
2017
FIGI
BBG00NSGPJD0
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.
Short DYNA short at 19.73 to 16.42 with the necessary risk management will bring a 16.79%+ return 2.2+ million volume
DYN - Falling WedgeOn the chart, we can se a falling wedge occurring.
The stock has held its strong support for a long period of time, and we are now expecting it to go to the upside after bullish consolidation.
MACD seems to make either a consolidating or bullish crossing.
Our first target is based on the forming,
Successful Inverted H&S Pattern Displaying the features of a inverted H&S pattern
The best chance of catching a bull run is on the right arm
$DYN is giving a GREAT IPO LONG opportunity todayIPO intraday trading strategy idea
Dyne Therapeutics is a pre-clinical stage developer of treatment candidates for various serious muscle diseases.
The share price is rising and gonna continue this trend today.
The demand for shares of the company still looks higher than the supply.
These and ot
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of DYN is 24.98 USD — it has decreased by 1.81% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Dyne Therapeutics, Inc. stocks are traded under the ticker DYN.
Dyne Therapeutics, Inc. is going to release the next earnings report on May 1, 2024. Keep track of upcoming events with our Earnings Calendar.
DYN stock is 3.97% volatile and has beta coefficient of 2.16. Check out the list of the most volatile stocks — is Dyne Therapeutics, Inc. there?
DYN earnings for the last quarter are −0.99 USD per share, whereas the estimation was −0.83 USD resulting in a −18.92% surprise. The estimated earnings for the next quarter are −0.92 USD per share. See more details about Dyne Therapeutics, Inc. earnings.
Yes, you can track Dyne Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
DYN stock has fallen by 0.44% compared to the previous week, the month change is a 1.96% rise, over the last year Dyne Therapeutics, Inc. has showed a 125.65% increase.
DYN net income for the last quarter is −66.64 M USD, while the quarter before that showed −60.21 M USD of net income which accounts for −10.68% change. Track more Dyne Therapeutics, Inc. financial stats to get the full picture.
Today Dyne Therapeutics, Inc. has the market capitalization of 2.03 B, it has increased by 0.97% over the last week.
No, DYN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, DYN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Dyne Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 141.00 employees. See our rating of the largest employees — is Dyne Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Dyne Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Dyne Therapeutics, Inc. stock shows the buy signal. See more of Dyne Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Dyne Therapeutics, Inc. future price: according to them, DYN price has a max estimate of 47.00 USD and a min estimate of 25.00 USD. Read a more detailed Dyne Therapeutics, Inc. forecast: see what analysts think of Dyne Therapeutics, Inc. and suggest that you do with its stocks.